Detalhe da pesquisa
1.
Induction of more aggressive tumoral phenotypes in LNCaP and PC3 cells by serum exosomes from prostate cancer patients.
Int J Cancer
; 153(10): 1829-1841, 2023 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37526104
2.
Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).
Prostate
; 82(8): 933-941, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35322894
3.
Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists.
Invest New Drugs
; 38(3): 746-754, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31312936
4.
Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
Prostate
; 78(12): 915-926, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29748961
5.
Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligands.
Eur J Inorg Chem
; 2015(13): 2295-2307, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27175101
6.
Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
Invest New Drugs
; 32(5): 871-82, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25000999
7.
Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
Biochim Biophys Acta
; 1823(10): 1676-85, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22728770
8.
Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Int J Cancer
; 132(4): 755-65, 2013 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22777643
9.
Carbohydrate effect of novel arene Ru(II) phenanthroline-glycoconjugates on metastatic biological processes.
J Inorg Biochem
; 247: 112326, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37478778
10.
Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095).
Int J Cancer
; 127(8): 1813-22, 2010 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20099275
11.
Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer.
Eur J Med Chem
; 199: 112414, 2020 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32438200
12.
Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Prostate
; 69(7): 774-86, 2009 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19189304
13.
Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.
Mol Cell Endocrinol
; 302(1): 41-8, 2009 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19101605
14.
Water soluble, optically active monofunctional Pd(ii) and Pt(ii) compounds: promising adhesive and antimigratory effects on human prostate PC-3 cancer cells.
Dalton Trans
; 48(38): 14279-14293, 2019 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31482936
15.
Insight into the antitumor activity of carbosilane Cu(ii)-metallodendrimers through their interaction with biological membrane models.
Nanoscale
; 11(28): 13330-13342, 2019 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31271405
16.
Biological evaluation of water soluble arene Ru(II) enantiomers with amino-oxime ligands.
J Inorg Biochem
; 183: 32-42, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29529470
17.
Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
Mol Cell Endocrinol
; 270(1-2): 8-16, 2007 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-17434257
18.
Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Int J Oncol
; 31(5): 1223-30, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17912451
19.
Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model.
Peptides
; 28(9): 1896-901, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17544169
20.
Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.
Regul Pept
; 144(1-3): 101-8, 2007 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-17683807